Levy Guy
Insider CIK 1812305 · LYRA 10% owner · PBLS 10% owner · BCAB Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| PBLS Parabilis Medicines, Inc. | C Conversion deriv | 2026-06-11 | 2026-06-29 | 527,070 | — | $0 | 0 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | P Buy | 2026-06-11 | 2026-06-29 | 375,000 | $20.00 | $7.50M | 1,027,000 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | C Conversion | 2026-06-11 | 2026-06-29 | 527,070 | $9.48 | $5.00M | 527,070 | SEC↗ |
| PBLS Parabilis Medicines, Inc. | P Buy | 2026-06-11 | 2026-06-29 | 125,000 | $20.00 | $2.50M | 652,000 | SEC↗ |
| BCAB BioAtla, Inc. | A Award | 2021-09-30 | 2021-09-30 | 267,900 | $28.00 | $7.50M | 1,115,817 | SEC↗ |
| BCAB BioAtla, Inc. | S Sale | 2021-08-24 | 2021-08-26 | 207,640 | $39.65 | $8.23M | 847,917 | SEC↗ |
| BCAB BioAtla, Inc. | S Sale | 2021-08-24 | 2021-08-26 | 53,195 | $39.65 | $2.11M | 217,358 | SEC↗ |
| BCAB BioAtla, Inc. | S Sale | 2021-08-24 | 2021-08-26 | 285,874 | $39.65 | $11.33M | 1,167,378 | SEC↗ |
| BCAB BioAtla, Inc. | S Sale | 2021-06-17 | 2021-06-21 | 337,220 | $39.16 | $13.21M | 1,453,252 | SEC↗ |
| BCAB BioAtla, Inc. | S Sale | 2021-06-17 | 2021-06-21 | 62,780 | $39.16 | $2.46M | 270,553 | SEC↗ |
| BCAB BioAtla, Inc. | A Award deriv | 2021-06-15 | 2021-06-16 | 12,307 | — | $0 | 12,307 | SEC↗ |
| BCAB BioAtla, Inc. | C Conversion deriv | 2020-12-18 | 2020-12-22 | 1,790,472 | — | $0 | 0 | SEC↗ |
| BCAB BioAtla, Inc. | P Buy | 2020-12-18 | 2020-12-22 | 333,333 | $18.00 | $6.00M | 333,333 | SEC↗ |
| BCAB BioAtla, Inc. | P Buy | 2020-12-18 | 2020-12-22 | 1,055,557 | $18.00 | $19.00M | 1,055,557 | SEC↗ |
| BCAB BioAtla, Inc. | C Conversion | 2020-12-18 | 2020-12-22 | 1,790,472 | — | $0 | 1,790,472 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | C Conversion deriv | 2020-05-05 | 2020-05-15 | 3,607,224 | — | $0 | 0 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | X Exercise deriv | 2020-05-05 | 2020-05-15 | 31,382 | — | $0 | 0 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | C Conversion deriv | 2020-05-05 | 2020-05-15 | 11,666,666 | — | $0 | 0 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | X Exercise | 2020-05-05 | 2020-05-15 | 31,382 | $8.63 | $270.8K | 474,330 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | C Conversion | 2020-05-05 | 2020-05-15 | 104,608 | — | $0 | 442,948 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | C Conversion | 2020-05-05 | 2020-05-15 | 338,330 | — | $0 | 338,330 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | P Buy | 2020-05-05 | 2020-05-15 | 155,000 | $16.00 | $2.48M | 155,000 | SEC↗ |
| LYRA Lyra Therapeutics, Inc. | S Sale | 2020-05-05 | 2020-05-15 | 16,909 | $16.00 | $270.5K | 457,421 | SEC↗ |